phase i study of tak-676 pembrolizumab following radiotherapy in late-line nsclc, tnbc and scchn
Published 2 years ago • 101 plays • Length 0:50Download video MP4
Download video MP3
Similar videos
-
0:43
expanding the functions of radiation therapy
-
2:03
antibiotics impact outcomes with pembrolizumab in nsclc patients
-
1:20
resistance to immune checkpoint blockade in patients with cscc
-
0:54
neon-1 & neon-2: alpn-202 alone or with pembrolizumab in patients with advanced malignancies
-
3:34
clinical outcomes of immunotherapy after radiographic progression in advanced nsclc
-
2:47
update from a phase 1 study of amg 757 in sclc
-
1:33
dr. anne chiang on molecular testing in lung cancer treatment planning
-
5:08
ultimate study: paclitaxel bevacizumab in non-squamous nsclc
-
2:15
what is t790m?
-
7:19
keynote-555: pembrolizumab bioavailability after subcutaneous administration in melanoma
-
1:07
phase ii results for pembrolizumab monotherapy in metastatic tnbc
-
0:50
targeted option for non-small cell lung cancer #2023 #oncology #lungcancer
-
1:32
i'm very optimistic. for the first time.
-
7:56
histology matters: individualizing treatment in non-small cell lung cancer
-
1:47
dr. paik on resistance mutations in nsclc
-
7:31
outcomes of first-line pembrolizumab monotherapy for pd-l1–positive metastatic nsclc
-
2:50
targeted therapy options for small cell lung cancer – anlotinib
-
2:49
what is multi-focal lung cancer?
-
2:31
transformed sclc: emerging science on histologic subtype switching